Traveling Exhibit of Cancer Educational Material

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 7
Volume 7
Issue 7

MADISON, Wisconsin--The Am-erican Association for Cancer Education (AACE) and the European Association for Cancer Education have joined with the WHO International Network for Cancer Education (INCE) to put together a traveling exhibit of cancer educational materials for display at cancer congresses around the world.

MADISON, Wisconsin--The Am-erican Association for Cancer Education (AACE) and the European Association for Cancer Education have joined with the WHO International Network for Cancer Education (INCE) to put together a traveling exhibit of cancer educational materials for display at cancer congresses around the world.

The next major display of the exhibit will be at the 17th International Cancer Congress in Rio de Janeiro, August 23-28, 1998. The NCI in Rio has agreed to accept educational materials prior to the meeting and hold them for the INCE to transfer to the exhibit site.

Educational materials suitable for such an exhibit can be sent to: Evaldo Abren, M.D.-Coordinator Pro-Onco; Av. Venezuela, 134, bloco A; 20081-370 Rio de Janeiro-RJ; Brasil.

Articles in this issue
Calling the National Cancer Institute
Six Cycles of AT Found Safe in Advanced Breast Cancer
New Drug Promising in Advanced Pancreatic Cancer
Herceptin/Chemo Effective in Metastatic Breast Cancer
Virtual Reality Exhibit Simulates Cancer Fatigue
New Director of AIDS Research
Exhibit Explores Healing Power of Creating Artwork
Update on Trials of Thrombopoietin for Platelet Recovery
Amifostine Reduces Xerostomia After RT for Head and Neck Cancer
National Survey Documents Gap in Quality of HIV/AIDS Care
Taxotere Improves Survival More than MV in Anthracycline-Resistant Breast Cancer
Stomach Cancer Susceptibility Gene Found in the Maori
Study Shows 6-Month Chemo Regimen Should Be New Colon Cancer Standard
Nurses Urged to Be Alert for Depression in Cancer Patients
Androgen Ablation Added to RT Improves Outcome in Locally Advanced Prostate Cancer
Recent Videos
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
2 experts are featured in this series.
Related Content
The 24-month RFS rates were 95.1%, 81.2%, 69.4%, and 48.4% in patients with stage III melanoma who experienced a pCR, near pCR, pPR, pNR, respectively.

Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma

Caroline Seymour
November 5th 2025
Article

The 24-month RFS rates were 95.1%, 81.2%, 69.4%, and 48.4% in patients with stage III melanoma who experienced a pCR, near pCR, pPR, pNR, respectively.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD
November 3rd 2025
Podcast

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?

Ariana Pelosci
November 5th 2025
Article

Aditya Bardia, MD, highlights the successes and challenges associated with ADC treatments in breast cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Russ Conroy
November 4th 2025
Article

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.

Lifileucel Confers Durable Responses in Pretreated Advanced NSCLC Type

Roman Fabbricatore
November 4th 2025
Article

Improvements in safety were observed without compromising efficacy after non-myeloablative lymphodepletion was reduced in this NSCLC population.